<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>gabapentin enacarbil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08872</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Gabapentin enacarbil is marketed under the name Horizant&#174;. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (<span class="caps">RLS</span>) and postherpetic neuralgia (<span class="caps">PHN</span>).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08872/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08872/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08872.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08872.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08872.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08872.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08872.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08872">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>HORIZANT</td><td>GLAXO GRP LTD</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>478296-72-9</td></tr><tr><th>Weight</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Chemical Formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI Key</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>IUPAC Name</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SMILES</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).</td></tr><tr><th>Pharmacodynamics</th><td>Since gabapentin enacarbil is a prodrug of gabapentin, it's physiological effects are the same as gabapentin. Concerning PHN, gabapentin prevents allodynia and hyperalgesia.
</td></tr><tr><th>Mechanism of action</th><td>Although the exact mechanism of action of gabapentin in RLS and PHN is unknown, it is presumed to involve the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. </td></tr><tr><th>Absorption</th><td>Gabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1. </td></tr><tr><th>Volume of distribution</th><td><p>The volume of distribution is 76L.</p></td></tr><tr><th>Protein binding</th><td>Gabapentin plasma protein binding is less than 3%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Gabapentin enacarbil does not interact with any of the major cytochrome P450 
enzymes. </p></td></tr><tr><th>Route of elimination</th><td>Gabapentin enacarbil is eliminated primarily in the urine (94%) and to a lesser extent in the feces (5%).</td></tr><tr><th>Half life</th><td>The elimination half-life of gabapentin is 5.1 to 6.0 hours.</td></tr><tr><th>Clearance</th><td><p>Renal clearance of gabapentin is 5 to 7 L/hr.</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions are headache, dizziness, and somnolence.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, extended release</td><td>Oral</td><td>300MG</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>600MG </td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>Melting onset of about 64&#176;C.</td><td>From FDA label.</td></tr><tr><td>water solubility</td><td>Solubility of 0.5 mg/mL in water </td><td>From FDA label.</td></tr><tr><td>pKa</td><td>pKa 5.0</td><td>From The Merck Index.</td></tr></table></td></tr><tr><th>Predicted Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14.</p></span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15146029">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D09539" target="_blank">D09539 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=68840" target="_blank">68840 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1628502" target="_blank">CHEMBL1628502 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/horizant-drug.htm" target="_blank">http://www.rxlist.com/horizant-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/sfx/gabapentin-enacarbil-side-effects.html" target="_blank">http://www.drugs.com/sfx/gabapentin-enacarbil-side-effects.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Gabapentin_enacarbil" target="_blank">Gabapentin_enacarbil <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08872.pdf?1367530848">show</a>(347 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08872.pdf?1367533200">show</a>(30.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00972">Azelastine</a></td><td>Avoid combination due to increased CNS depression.</td></tr><tr><td><a href="/drugs/DB00898">Ethanol</a></td><td>Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>No food effects.</li></ul></td></tr></tbody></table>